OncoMatch/Clinical Trials/NCT06178614

A Study of JNJ-87890387 for Advanced Solid Tumors

Is NCT06178614 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies JNJ-87890387 for neoplasms.

Phase 1RecruitingJanssen Research & Development, LLCNCT06178614Data as of Jun 2026Location: United States · France · Spain

Treatment: JNJ-87890387 — The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

JNJ-87890387

Cancer type

Tumor Agnostic

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Start Midwest · Grand Rapids, Michigan
Sarah Cannon Research Institute · Nashville, Tennessee

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06178614 currently recruiting?

Yes, this trial is currently recruiting patients.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify